ENGLEWOOD, Colo., Nov. 9, 2023
/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical
technology company specializing in the manufacture and sale of
non-invasive medical devices for pain management, rehabilitation,
and patient monitoring, today announced the Company has been
ranked among all companies in the U.S. and Canada between 2019 and 2022 on Deloitte's
Technology Fast 500. Zynex's revenues grew 248% over that period,
with 2022 revenue reaching $158.2
million. The company estimates 2023 revenue between
$189.5 and $194.5 million. The 2023 Deloitte Technology Fast
500 list can be found at www.fast500.com.
"We are honored to be included in Deloitte's Technology Fast 500
list for the fifth year in a row and ninth time overall,"
said Thomas Sandgaard, CEO of Zynex. "Our vision is to be the
world's premier pain management provider. Continued revenue and
earnings growth and recognition by organizations such as Deloitte
reinforce our conviction that Zynex is on the right path toward
that goal."
"As for growing companies, it's always rewarding to be
recognized for the ongoing commitment it takes to navigate
obstacles, transform when necessary and ultimately create a
thriving business," said Christie
Simons, partner, Deloitte & Touche LLP and industry
leader for technology, media and telecommunications within
Deloitte's Audit & Assurance practice. "Over the nearly 30
years we've been compiling the Technology Fast 500, we've seen new
categories emerge, growth rates explode, and certain regional
markets shine from the bright talent they attract. We are proud of
all the winners for achieving this well-deserved honor."
About Deloitte's 2023 Technology Fast 500™
Now in its 29th year, the Deloitte Technology Fast 500 provides
a ranking of the fastest-growing technology, media,
telecommunications, life sciences, fintech, and energy tech
companies — both public and private — in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2019 to 2022.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000, and current-year operating revenues of
at least $5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North
America.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and
sells medical devices used for pain management and rehabilitation
as well as non-invasive fluid, sepsis, and laser-based pulse
oximetry monitoring systems for use in hospitals. For additional
information, please visit: www.zynex.com.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and
advisory services to many of the world's most admired brands,
including nearly 90% of the Fortune 500® and more than 8,500
U.S.-based private companies. At Deloitte, we strive to live our
purpose of making an impact that matters by creating trust and
confidence in a more equitable society. We leverage our unique
blend of business acumen, command of technology, and strategic
technology alliances to advise our clients across industries as
they build their future. Deloitte is proud to be part of the
largest global professional services network serving our clients in
the markets that are most important to them. Bringing more than 175
years of service, our network of member firms spans more than 150
countries and territories. Learn how Deloitte's approximately
457,000 people worldwide connect for impact
at www.deloitte.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-named-as-a-winner-in-the-deloitte-2023-technology-fast-500-awards-for-the-5th-consecutive-year-301983266.html
SOURCE Zynex